

Ran Xue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9085871/publications.pdf>

Version: 2024-02-01

23
papers

510
citations

758635

12
h-index

676716

22
g-index

23
all docs

23
docs citations

23
times ranked

700
citing authors

#	ARTICLE	IF	CITATIONS
1	Ferroptosis in liver disease: new insights into disease mechanisms. <i>Cell Death Discovery</i> , 2021, 7, 276.	2.0	107
2	A Rising Star in Pancreatic Diseases: Pancreatic Stellate Cells. <i>Frontiers in Physiology</i> , 2018, 9, 754.	1.3	83
3	Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-8.	1.9	41
4	Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway. <i>Oncotarget</i> , 2017, 8, 92300-92311.	0.8	38
5	Coenzyme Q10 Ameliorates Pancreatic Fibrosis via the ROS-Triggered mTOR Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-10.	1.9	35
6	Clinical performance of stem cell therapy in patients with acute-on-chronic liver failure: a systematic review and meta-analysis. <i>Journal of Translational Medicine</i> , 2018, 16, 126.	1.8	25
7	The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1503-1511.	1.4	24
8	Mitofusin2, as a Protective Target in the Liver, Controls the Balance of Apoptosis and Autophagy in Acute-on-Chronic Liver Failure. <i>Frontiers in Pharmacology</i> , 2019, 10, 601.	1.6	20
9	Mitofusin2, a rising star in acute-on-chronic liver failure, triggers macroautophagy via the mTOR signalling pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7810-7818.	1.6	18
10	The Management of Glucocorticoid Therapy in Liver Failure. <i>Frontiers in Immunology</i> , 2019, 10, 2490.	2.2	17
11	Nrf2-Mediated Ferroptosis Inhibition Exerts a Protective Effect on Acute-on-Chronic Liver Failure. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-23.	1.9	17
12	Derivation and Validation of the Potential Core Genes in Pancreatic Cancer for Tumor-Stroma Crosstalk. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	14
13	A novel dynamic model for predicting outcome in patients with hepatitis B virus related acute-on-chronic liver failure. <i>Oncotarget</i> , 2017, 8, 108970-108980.	0.8	13
14	Liver function and energy metabolism in hepatocellular carcinoma developed in patients with hepatitis B-related cirrhosis. <i>Medicine (United States)</i> , 2019, 98, e15528.	0.4	12
15	The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial. <i>BMC Medicine</i> , 2020, 18, 383.	2.3	11
16	The assessment of multipotent cell transplantation in acute-on-chronic liver failure: a systematic review and meta-analysis. <i>Translational Research</i> , 2018, 200, 65-80.	2.2	9
17	The clinical parameters for the diagnosis of hepatitis B virus related acute-on-chronic liver failure with sepsis. <i>Scientific Reports</i> , 2019, 9, 2558.	1.6	6
18	Characterization of metabolic landscape in hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1144-1156.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	5
20	PINK1 ameliorates acute-on-chronic liver failure by inhibiting apoptosis through mTORC2/AKT signaling. Cell Death Discovery, 2022, 8, 222.	2.0	4
21	Worse or better?â€”Cirrhosis with hepatocellular carcinoma. Medical Hypotheses, 2016, 97, 85-87.	0.8	2
22	A phase 1b/2 trial of SHR-1701 in combination with gemcitabine and nab-paclitaxel in patients with untreated locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, e16264-e16264.	0.8	2
23	Novel Prognostic Models for Predicting the 180-Day Outcome for Patients with Hepatitis-B Virus-related Acute-on-chronic Liver Failure. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	1